CorMedix Inc. (CRMD) Form 8-K — Nov 2, 2026
CorMedix reported unaudited cash of approximately $355 million as of September 30, 2026 and reaffirmed its full-year 2026 total revenue guidance of $325 million to $345 million. CMS's 2027 ESRD PPS final rule set the Q1 2027 post-TDAPA Add-on for DefenCath at $8.32 per dialysis session, within the company's guided range of 3x-5x the current $2.37 rate, and introduced a new quarterly process for calculating Add-on adjustments. CorMedix pushed back on an unnamed large dialysis organization's projections of 2027 Add-on quarterly trajectory, saying it has not shared utilization or pricing data with any third party.
Key figures
- Guidance
- Reaffirmed FY2026 total revenue guidance of $325M-$345M
- Cash Position
- 355000000
- Expected 2027 avg addon
- more than 2x the current rate of $2.37
- Q1 2027 defencath addon per session
- 8.32
- Current addon per session q3 q4 2026
- 2.37
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.